Interrelationship between chronic obstructive pulmonary disease and COVID-19

Автор: Khakimova Ruza Abdurahimovna, Makhsumova Dinora Kamolovna, Nugmanov Ozodbek Zhuraboy

Статья в выпуске: 2 (10), 2022 года.

Бесплатный доступ

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that makes it hard to breathe. Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing. It's typically caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer and a variety of other conditions. Given the devastating impact that COVID-19 can have on the lung, it is natural to fear for patients with underlying COPD. Estimating their excess risk for contracting COVID- 19 and, in particular, its more severe respiratory manifestations has been a challenging exercise in this pandemic for various reasons. Thus, in this article we will discuss interrelationship between chronic obstructive pulmonary disease and COVID-19.

Еще

Chronic obstructive pulmonary disease, chronic inflammatory, cough, mucus, wheezing, lung cancer, COVID-19

Короткий адрес: https://sciup.org/14124736

IDR: 14124736

Список литературы Interrelationship between chronic obstructive pulmonary disease and COVID-19

Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD executive summary. Eur Respir J 2017; 49:214–246.
Singh D, Long G, Cancado JED, Higham A. Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician. Curr Opin Pulm Med 2020; 26:162–168.
Sajjan US. Susceptibility to viral infections in chronic obstructive pulmonary disease: role of epithelial cells. Curr Opin Pulm Med 2013; 19:125–132.
Centers for Disesase Control and Prevention. Excess Deaths Associated with COVID-19. 2020. www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm Date last accessed: 3 May 2020.
Michelozzi P, de’Donato F, Scortichini M, et al. Mortality impacts of the coronavirus disease (COVID-19) outbreak by sex and age: rapid mortality surveillance system, Italy, February to 18 April 2020. Euro Surveill 2020; 25: 2000620.
Gershon AS, Thiruchelvam D, Chapman KR, et al. Health services burden of undiagnosed and overdiagnosed COPD. Chest 2018; 153: 1336–1346.
Labonte LE, Tan WC, Li PZ, et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD Study. Am J Respir Crit Care Med 2016; 194: 285–298.
Martinez CH, Mannino DM, Jaimes FA, et al. Undiagnosed obstructive lung disease in the United States. Associated factors and long-term mortality. Ann Am Thorac Soc 2015; 12: 1788–1795.
Leung, Janice M.; Niikura, Masahiro; Yang, Cheng Wei Tony; Sin, Don D. (2020). COVID-19 and COPD. European Respiratory Journal, 56(2), 2002108–. doi:10.1183/13993003.02108-2020.
Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450–454.11. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280.
Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020; 5: 562–569.
Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181: 281–292.
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–273.
Leung JM, Yang CX, Tam A, et al. ACE-2 Expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55: 2000688.
Cai G, Bosse Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med 2020; 201: 1557–1559.
Li G, He X, Zhang L, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun 2020; 112: 102463.
Zhang H, Rostami MR, Leopold PL, et al. Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium. Am J Respir Crit Care Med 2020; 202: 219–229.
Leung JM, Yang CX, Sin DD. COVID-19 and nicotine as a mediator of ACE-2. Eur Respir J 2020; 55: 2001261.
Russo P, Bonassi S, Giacconi R, et al. COVID-19 and smoking: is nicotine the hidden link? Eur Respir J 2020; 55: 2001116.
Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020; 26: 681–687.
Chronic obstructive pulmonary disease and COVID-19: interrelationships. Singh, Davea,b; Mathioudakis, Alexander G.a; Higham, Andrewa. doi: 10.1097/MCP.0000000000000834.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181:271–280. e8.
Liu J, Li Y, Liu Q, et al. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov 2021; 7:17.
Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011; 183:734–742.
Garcia-Valero J, Olloquequi J, Montes JF, et al. Deficient pulmonary IFN-beta expression in COPD patients. PLoS One 2019; 14:e0217803.
Singanayagam A, Loo SL, Calderazzo M, et al. Antiviral immunity is impaired in COPD patients with frequent exacerbations. Am J Physiol Lung Cell Mol Physiol 2019; 317:L893–L903.
Grundy S, Plumb J, Lea S, et al. Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. PLoS One 2013; 8:e71629.
Roberts MEP, Higgs BW, Brohawn P, et al. CD4+ T-cell profiles and peripheral blood ex-vivo responses to TCell directed stimulation delineate COPD phenotypes. Chronic Obstr Pulm Dis 2015; 2:268–280. 30. Mj
Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci 2020;75: 2231–2232.
Ahmetov II, Borisov OV, Semenova EA, Andryushchenko ON, Andryushchenko LB, Generozov EV, et al. Team sport, power, and combat athletes are at high genetic risk for coronavirus disease-2019 severity. J Sport Health Sci 2020;9:430–431.
Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet 2018;19:581–590.
Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med 2020;167:105941.
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020;12:6049–6057.
Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol 2020;92:1915–1921.
Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Jr., Liang L. Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data. Metabolism 2020;112:154345.
Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divall P, et al. The impact of ethnicity on clinical outcomes in COVID-19: a systematic review. EClinicalMedicine 2020;23:100404.

Еще

Статья научная